• 1
    D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006; 44: 217-231.
  • 2
    Ripoll C, Groszmann R, Garcia-Tsao G, Grace N, Burroughs A, Planas R, et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology 2007; 133: 481-488.
  • 3
    Baik SK, Park DH, Kim MY, Choi YJ, Kim HS, Lee DK, et al. Captopril reduces portal pressure effectively in portal hypertensive patients with low portal venous velocity. J Gastroenterol 2003; 38: 1150-1154.
  • 4
    Kim MY, Baik SK, Park DH, Lim DW, Kim JW, Kim HS, et al. Damping index of Doppler hepatic vein waveform to assess the severity of portal hypertension and response to propranolol in liver cirrhosis: a prospective nonrandomized study. Liver Int 2007; 27: 1103-1110.
  • 5
    Lebrec D. Methods to evaluate portal hypertension. Gastroenterol Clin North Am 1992; 21: 41-59.
  • 6
    Baik SK, Jeong PH, Ji SW, Yoo BS, Kim HS, Lee DK, et al. Acute hemodynamic effects of octreotide and terlipressin in patients with cirrhosis: a randomized comparison. Am J Gastroenterol 2005; 100: 631-635.
  • 7
    Baik SK, Kim JW, Kim HS, Kwon SO, Kim YJ, Park JW, et al. Recent variceal bleeding: Doppler US hepatic vein waveform in assessment of severity of portal hypertension and vasoactive drug response. Radiology 2006; 240: 574-580.
  • 8
    Merkel C, Sacerdoti D, Bolognesi M, Bombonato G, Gatta A. Doppler sonography and hepatic vein catheterization in portal hypertension: assessment of agreement in evaluating severity and response to treatment. J Hepatol 1998; 28: 622-630.
  • 9
    Choi YJ, Baik SK, Park DH, Kim MY, Kim HS, Lee DK, et al. Comparison of Doppler ultrasonography and the hepatic venous pressure gradient in assessing portal hypertension in liver cirrhosis. J Gastroenterol Hepatol 2003; 18: 424-429.
  • 10
    Baik SK. Haemodynamic evaluation by Doppler ultrasonography in patients with portal hypertension: a review. Liver Int 2010; 30: 1403-1413.
  • 11
    Blomley MJ, Cooke JC, Unger EC, Monaghan MJ, Cosgrove DO. Microbubble contrast agents: a new era in ultrasound. BMJ 2001; 322: 1222-1225.
  • 12
    Frinking PJ, de Jong N. Acoustic modeling of shell-encapsulated gas bubbles. Ultrasound Med Biol 1998; 24: 523-533.
  • 13
    Harvey CJ, Blomley MJ, Eckersley RJ, Cosgrove DO. Developments in ultrasound contrast media. Eur Radiol 2001; 11: 675-689.
  • 14
    Albrecht T, Blomley MJ, Cosgrove DO, Taylor-Robinson SD, Jayaram V, Eckersley R, et al. Non-invasive diagnosis of hepatic cirrhosis by transit-time analysis of an ultrasound contrast agent. Lancet 1999; 353: 1579-1583.
  • 15
    Blomley MJ, Lim AK, Harvey CJ, Patel N, Eckersley RJ, Basilico R, et al. Liver microbubble transit time compared with histology and Child-Pugh score in diffuse liver disease: a cross sectional study. Gut 2003; 52: 1188-1193.
  • 16
    Lim AK, Taylor-Robinson SD, Patel N, Eckersley RJ, Goldin RD, Hamilton G, et al. Hepatic vein transit times using a microbubble agent can predict disease severity non-invasively in patients with hepatitis C. Gut 2005; 54: 128-133.
  • 17
    Grier S, Lim AK, Patel N, Cobbold JF, Thomas HC, Cox IJ, et al. Role of microbubble ultrasound contrast agents in the non-invasive assessment of chronic hepatitis C-related liver disease. World J Gastroenterol 2006; 12: 3461-3465.
  • 18
    Groszmann RJ, Wongcharatrawee S. The hepatic venous pressure gradient: anything worth doing should be done right. HEPATOLOGY 2004; 39: 280-282.
  • 19
    Kim MY, Baik SK, Yea CJ, Lee IY, Kim HJ, Park KW, et al. Hepatic venous pressure gradient can predict the development of hepatocellular carcinoma and hyponatremia in decompensated alcoholic cirrhosis. Eur J Gastroenterol Hepatol 2009; 21: 1241-1246.
  • 20
    de Franchis R. Updating consensus in portal hypertension: report of the Baveno III Consensus Workshop on definitions, methodology, and therapeutic strategies in portal hypertension. J Hepatol 2000; 33: 846-852.
  • 21
    Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983; 148: 839-843.
  • 22
    Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143: 29-36.
  • 23
    Quaia E, Calliada F, Bertolotto M, Rossi S, Garioni L, Rosa L, Pozzi-Mucelli R. Characterization of focal liver lesions with contrast-specific US modes and a sulfur hexafluoride-filled microbubble contrast agent: diagnostic performance and confidence. Radiology 2004; 232: 420-430.
  • 24
    Blomley MJ, Albrecht T, Cosgrove DO, Jayaram V, Eckersley RJ, Patel N, et al. Liver vascular transit time analyzed with dynamic hepatic venography with bolus injections of an US contrast agent: early experience in seven patients with metastases. Radiology 1998; 209: 862-866.
  • 25
    Sugimoto H, Kaneko T, Hirota M, Tezel E, Nakao A. Earlier hepatic vein transit-time measured by contrast ultrasonography reflects intrahepatic hemodynamic changes accompanying cirrhosis. J Hepatol 2002; 37: 578-583.
  • 26
    Kim MY, Baik SK, Lee SS. Hemodynamic alterations in cirrhosis and portal hypertension. Korean J Hepatol 2010; 16: 347-352.
  • 27
    Ohnishi K, Chin N, Saito M, Tanaka H, Terabayashi H, Nakayama T, et al. Portographic opacification of hepatic veins and (anomalous) anastomoses between the portal and hepatic veins in cirrhosis–indication of extensive intrahepatic shunts. Am J Gastroenterol 1986; 81: 975-978.
  • 28
    Schrier RW. Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy (2). N Engl J Med 1988; 319: 1127-1134.
  • 29
    Lautt WW. Mechanism and role of intrinsic regulation of hepatic arterial blood flow: hepatic arterial buffer response. Am J Physiol 1985; 249: G549-G556.
  • 30
    Kleber G, Steudel N, Behrmann C, Zipprich A, Hubner G, Lotterer E, Fleig WE. Hepatic arterial flow volume and reserve in patients with cirrhosis: use of intra-arterial Doppler and adenosine infusion. Gastroenterology 1999; 116: 906-914.
  • 31
    Bosch J, Garcia-Pagan JC, Berzigotti A, Abraldes JG. Measurement of portal pressure and its role in the management of chronic liver disease. Semin Liver Dis 2006; 26: 348-362.
  • 32
    Berzigotti A, Nicolau C, Bellot P, Abraldes JG, Gilabert R, Garcia-Pagan JC, Bosch J. Evaluation of regional hepatic perfusion (RHP) by contrast-enhanced ultrasound in patients with cirrhosis. J Hepatol 2011; 55: 307-314.
  • 33
    Huet PM, Goresky CA, Villeneuve JP, Marleau D, Lough JO. Assessment of liver microcirculation in human cirrhosis. J Clin Invest 1982; 70: 1234-1244.
  • 34
    Lim AK, Patel N, Eckersley RJ, Goldin RD, Thomas HC, Cosgrove DO, et al. Hepatic vein transit time of SonoVue: a comparative study with Levovist. Radiology 2006; 240: 130-135.